18F-BMS-986229

N/A

Report date: 2025/01/07 17:01:01

Base Information

Drug Name18F-BMS-986229
Drug Alias NamePD-L1 adnectin PET tracer18F-BMS-986229[18F]BMS-986229
ClassificationDiagnostic agent (In vivo) > Radionuclide Imaging agentRadiation-emitting products > Radioactive diagnostic agent
Mechanisms of ActionRadionuclide imaging enhancersPositron-emission tomography enhancersProgrammed death-ligand 1 modulators
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsEsophageal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesRomania +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb International CorpPeptiDream Inc
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer CenterBristol-Myers Squibb International Corp
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsEsophageal Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A